Evaluation of Plasma Concentrations of Galectins-1, 2 and 12 in Psoriasis and Their Clinical Implications
Biomolecules · 2023
DOI: 10.3390/biom13101472 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2023. Verfasst von Julia Nowowiejska und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, Medical University of Bialystok, Zurawia 14 St., 15-540 Bialystok, Poland. Hauptthemen laut MEDLINE: Psoriasis, Metabolic Diseases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Bialystok.
Abstract (Originalsprache)
Psoriasis is a complex disease that nowadays is considered not only a dermatosis but a kind of systemic disorder associated with many accompanying diseases. Metabolic complications leading to cardiovascular incidences are the cause of increased mortality in psoriatic patients. Galectins (gal) are beta-galactoside-binding lectins that exert different functions, including engagement in metabolic processes. Our aim was to assess the concentrations of gal-1, 2 and 12 in psoriatics, to establish their potential clinical implications, including in metabolic complications. Plasma galectins were assessed by ELISA in 60 psoriatic patients and 30 controls without dermatoses and a negative family history of psoriasis. Plasma concentrations of all galectins were significantly higher in patients than controls (gal-1 with p < 0.001, gal-2 and 12 with p < 0.05). There were no correlations between galectins concentrations and psoriasis severity in PASI or disease duration (p > 0.05). Gal-1 and 12 were significantly negatively correlated with GFR (p < 0.05, p < 0.01, respectively) and gal-2 with HDL (p < 0.05). Gal-2 was significantly positively correlated with CRP (p < 0.05) and gal-12 with fasting glucose (p < 0.01). Based on the results and given the reported role of galectins in metabolic disorders we may conclude that gal-1, 2 and 12 could be potentially engaged in metabolic complications in psoriatics, most probably in atherosclerosis. Gal-2 could be perhaps further investigated as a marker of metabolically induced inflammation in psoriasis, gal-1 and gal-12 as predictors of renal impairment in psoriatics due to metabolic disorders. Potentially, gal-12 could be considered in the future as a marker of carbohydrate metabolism disorders in psoriatics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Venereology, Medical University of Bialystok, Zurawia 14 St., 15-540 Bialystok, Poland.
- Department of Pharmacodynamics, Medical University of Bialystok, Mickiewicza 2C St., 15-089 Bialystok, Poland.
ORCID-Profile: Julia Nowowiejska, Anna Baran, Justyna Magdalena Hermanowicz, Dariusz Pawlak, Iwona Flisiak
Förderung
- Medical University of Bialystok
Zitieren
APA
Nowowiejska, J., Baran, A., Hermanowicz, J. M., Sieklucka, B., Pawlak, D., & Flisiak, I. (2023). Evaluation of Plasma Concentrations of Galectins-1, 2 and 12 in Psoriasis and Their Clinical Implications. Biomolecules. https://doi.org/10.3390/biom13101472
Vancouver
Nowowiejska J, Baran A, Hermanowicz JM, Sieklucka B, Pawlak D, Flisiak I. Evaluation of Plasma Concentrations of Galectins-1, 2 and 12 in Psoriasis and Their Clinical Implications. Biomolecules. 2023. doi:10.3390/biom13101472
BibTeX
@article{Nowowiejska2023,
author = {Nowowiejska, Julia and Baran, Anna and Hermanowicz, Justyna Magdalena and Sieklucka, Beata and Pawlak, Dariusz and Flisiak, Iwona},
title = {Evaluation of Plasma Concentrations of Galectins-1, 2 and 12 in Psoriasis and Their Clinical Implications},
journal = {Biomolecules},
year = {2023},
doi = {10.3390/biom13101472}
}
EUVIMED